Jaguar Health, Inc.: Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapySAN
Source: finanznachrichten.de